AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10079438 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification combined with trabeculectomy (P-T)
Number of subjects: 60
Study 7673531 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent focus intervention
Number of subjects: 158
Study 7673531 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen focus intervention
Number of subjects: 158
Study 7673531 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and teen focus intervention
Number of subjects: 158
Study 7673531 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed change (materials only)
Number of subjects: 158
Study 7673531 — intervention group
Group type: COMPARATOR
Intervention: Control group (quasi-experimental)
Number of subjects: 158
Study 7673531 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent focus condition
Number of subjects: 158
Study 7673531 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregated high-risk youths intervention
Number of subjects: 158
Study 2282293 — intervention group
Group type: EXPERIMENTAL
Intervention: Low osmolar contrast media
Number of subjects: 0
Study 2282293 — intervention group
Group type: COMPARATOR
Intervention: High osmolar contrast media
Number of subjects: 0
Study 7175716 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g probenecid
Number of subjects: 3
Study 7175716 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g probenecid
Number of subjects: 3
Study 7175716 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g probenecid
Number of subjects: 3
Study 30102620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking at the mother's breast (3 times a day for 5 minutes until nutritive breastfeeding started)
Number of subjects: 9
Study 30102620 — intervention group
Group type: COMPARATOR
Intervention: Standard care (nonnutritive sucking on a finger during gavage feeds)
Number of subjects: 9
Study 29449764 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroplasticity explanation with manual therapy
Number of subjects: 62
Study 29449764 — intervention group
Group type: COMPARATOR
Intervention: Mechanical explanation with manual therapy
Number of subjects: 62
Study 26374743 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine (NAC) 3 g/day (1.5 g twice daily)
Number of subjects: 44
Study 26374743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 24274912 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 152
Study 24274912 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin
Number of subjects: 152
Study 24274912 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 152
Study 24274912 — intervention group
Group type: COMPARATOR
Intervention: Control (spontaneous eradication)
Number of subjects: 152
Study 21337259 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted mental imagery
Number of subjects: 0
Study 21337259 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 0
Study 21337259 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal intention mental imagery
Number of subjects: 0
Study 21337259 — intervention group
Group type: COMPARATOR
Intervention: Active rehearsal (Control)
Number of subjects: 0
Study 19608151 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity resistance exercise training (n=80)
Number of subjects: 160
Study 19608151 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=80)
Number of subjects: 160
Study 19608151 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity resistance exercise training
Number of subjects: 160
Study 17631083 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of digoxin therapy
Number of subjects: 7788
Study 14716705 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg b.d.)
Number of subjects: 0
Study 14716705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14716705 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (100 mg per day for 7 days)
Number of subjects: 0
Study 14716705 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 0
Study 12803656 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatments for MG
Number of subjects: 0
Study 9845709 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopheresis
Number of subjects: 60
Study 9845709 — intervention group
Group type: COMPARATOR
Intervention: Standard triple-drug immunosuppressive therapy (cyclosporine, azathioprine, and prednisone)
Number of subjects: 60
Study 7852209 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) therapy
Number of subjects: 0
Study 7852209 — intervention group
Group type: COMPARATOR
Intervention: Allogenic blood transfusion
Number of subjects: 0
Study 3188866 — intervention group
Group type: EXPERIMENTAL
Intervention: Active physical therapy combined with 2 hours of passive knee motion twice daily from 2-12 days after total knee arthroplasty
Number of subjects: 54
Study 3188866 — intervention group
Group type: COMPARATOR
Intervention: Active physical therapy only
Number of subjects: 54
Study 31063264 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 0
Study 31063264 — intervention group
Group type: COMPARATOR
Intervention: Workshop intervention
Number of subjects: 0
Study 28644207 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic debridement with bromelain (NexoBrid, EDNX)
Number of subjects: 40
Study 28644207 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgical debridement (TSD)
Number of subjects: 40
Study 26715040 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented cognitive behavioural therapy (augmented CBT)
Number of subjects: 61
Study 26715040 — intervention group
Group type: COMPARATOR
Intervention: Computerized cognitive training program (CogniPlus)
Number of subjects: 61
Study 24220557 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU)
Number of subjects: 892
Study 24220557 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus oxaliplatin (FU + oxaliplatin)
Number of subjects: 892
Study 24220557 — intervention group
Group type: COMPARATOR
Intervention: Control group (FU)
Number of subjects: 892
Study 21720653 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus bioflavonoid blend
Number of subjects: 70
Study 21720653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19192463 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation and maintenance antidepressant medication
Number of subjects: 91
Study 19192463 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline predictors (higher level of personality pathology and higher level of education)
Number of subjects: 91
Study 16292319 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg
Number of subjects: 28
Study 16292319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15215815 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d for 1 week) plus Clopidogrel (75 mg/d for 3 weeks)
Number of subjects: 30
Study 15215815 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (international normalized ratio, 2 to 3 for 3 weeks)
Number of subjects: 30
Study 15215815 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus Clopidogrel
Number of subjects: 30
Study 15215815 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 30
Study 10679542 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic NCPAP
Number of subjects: 59
Study 10679542 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic NCPAP
Number of subjects: 59
Study 9316956 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 0.5 MAC
Number of subjects: 24
Study 9316956 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.5 MAC
Number of subjects: 24
Study 9316956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 MAC
Number of subjects: 24
Study 9316956 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane, Isoflurane, Sevoflurane at 1.5 MAC for 3 hours
Number of subjects: 24
Study 9316956 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane and Sevoflurane during burst suppression
Number of subjects: 24
Study 8398293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (1.6 g daily)
Number of subjects: 36
Study 8398293 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin (100 U)
Number of subjects: 36
Study 8398293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3598328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alpha-2 interferon (50 X 10(6) U/m2) on 5 consecutive days every 4 weeks
Number of subjects: 65
Study 3598328 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous alpha-2 interferon (20 X 10(6) U/m2) three times per week
Number of subjects: 65
Study 3598328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alpha-2 interferon (20 X 10(6) U/m2 per day) in combination with intravenous 5-Fluorouracil (250-500 mg/m2 per day on the first 5 days of each 4-week cycle)
Number of subjects: 65
Study 3598328 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous alpha-2 interferon (5 X 10(6) U/m2 per day) in combination with intravenous 5-Fluorouracil (250-500 mg/m2 per day on the first 5 days of each 4-week cycle)
Number of subjects: 65
Study 30924792 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) for managing chronic ulcers
Number of subjects: 0
Study 30924792 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) for surgical site infection (SSI) surveillance
Number of subjects: 0
Study 30924792 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) for postoperative wound care
Number of subjects: 0
Study 28606437 — intervention group
Group type: EXPERIMENTAL
Intervention: Price-aware group (surgeons received implant prices)
Number of subjects: 226
Study 28606437 — intervention group
Group type: COMPARATOR
Intervention: Price-naïve group (surgeons did not receive implant prices)
Number of subjects: 226
Study 28606437 — intervention group
Group type: EXPERIMENTAL
Intervention: Price-aware group
Number of subjects: 226
Study 28606437 — intervention group
Group type: COMPARATOR
Intervention: Price-naïve group
Number of subjects: 226
Study 28606437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 226
Study 26271904 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation (2 grams of choline bitartrate)
Number of subjects: 28
Study 26271904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23419552 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT) programme
Number of subjects: 199
Study 23419552 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 199
Study 23419552 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT in primary care setting
Number of subjects: 199
Study 21366899 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 87
Study 21366899 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 87
Study 21366899 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin and CRP
Number of subjects: 87
Study 18362366 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide plus dexamethasone (thal/dex)
Number of subjects: 470
Study 18362366 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dexamethasone (placebo/dex)
Number of subjects: 470
Study 19460056 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidification with CPAP (Fisher & Paykel HC201 pump with built-in heated humidification)
Number of subjects: 54
Study 19460056 — intervention group
Group type: COMPARATOR
Intervention: Non-humidification with CPAP (heater disabled and without water)
Number of subjects: 54
Study 16359965 — intervention group
Group type: EXPERIMENTAL
Intervention: Müllerian-inhibiting substance (MIS)
Number of subjects: 46
Study 16359965 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin B
Number of subjects: 46
Study 16359965 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone (LH)
Number of subjects: 46
Study 16359965 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 46
Study 16359965 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione (A)
Number of subjects: 46
Study 16359965 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin
Number of subjects: 46
Study 16359965 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 46
Study 16359965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian volume
Number of subjects: 46
Study 16359965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatility index
Number of subjects: 46
Study 16359965 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Inhibin B with MIS
Number of subjects: 46
Study 16359965 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of MIS with ovarian size
Number of subjects: 46
Study 16359965 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of MIS with reproductive hormones and insulin
Number of subjects: 46
Study 12099157 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren Ophtha CD
Number of subjects: 299
Study 12099157 — intervention group
Group type: COMPARATOR
Intervention: Voltaren Ophtha
Number of subjects: 299
Study 9496522 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 0.1 mg subcutaneously 30 min before and 8 and 16 hours after ERCP
Number of subjects: 73
Study 9496522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 8974349 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics
Number of subjects: 0
Study 8974349 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepine-treated normal volunteers
Number of subjects: 0
Study 3052555 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 20
Study 3052555 — intervention group
Group type: COMPARATOR
Intervention: Inactive transcutaneous electrical nerve stimulation (placebo)
Number of subjects: 20
Study 4620372 — intervention group
Group type: EXPERIMENTAL
Intervention: Butibufen
Number of subjects: 21
Study 31487271 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked dual-class drug resistance mutations (DRMs) present before ART initiation
Number of subjects: 0
Study 31487271 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked single-class drug resistance mutations (DRMs) present before ART initiation
Number of subjects: 0
Study 31487271 — intervention group
Group type: COMPARATOR
Intervention: Combination ART with 3 drugs (nevirapine/tenofovir/emtricitabine)
Number of subjects: 0
Study 28991344 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and systemic treatment (oral propranolol 1 mg/kg per day initially, increased to 2 mg/kg per day gradually in 2 weeks and timolol maleate 0.5% gel)
Number of subjects: 25
Study 28991344 — intervention group
Group type: COMPARATOR
Intervention: Systemic treatment only (oral propranolol 1 mg/kg per day initially, increased to 2 mg/kg per day gradually in 2 weeks and simple eye ointment)
Number of subjects: 25
Study 27306492 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral chlorzoxazone
Number of subjects: 110
Study 27306492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 24935081 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus home-based education
Number of subjects: 163
Study 24935081 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 163
Study 24935081 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based education for invitees
Number of subjects: 163
Study 24935081 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based education
Number of subjects: 163
Study 22016348 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (n = 17)
Number of subjects: 30
Study 22016348 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 30
Study 19535243 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF (adjuvant epirubicin-based chemotherapy)
Number of subjects: 647
Study 19535243 — intervention group
Group type: COMPARATOR
Intervention: CMF (adjuvant methotrexate-based chemotherapy)
Number of subjects: 647
Study 19535243 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP-1 status (positive or negative) versus treatment (CMF or CEF) interaction
Number of subjects: 647
Study 17513798 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging ELISA
Number of subjects: 1216
Study 17513798 — intervention group
Group type: EXPERIMENTAL
Intervention: Biacore biosensor immunoassay
Number of subjects: 1216
Study 15293606 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage LAUP treatment
Number of subjects: 25
Study 15293606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulated snore surgery followed by an oral placebo)
Number of subjects: 25
Study 11887802 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate-based solution (B/L)
Number of subjects: 92
Study 11887802 — intervention group
Group type: COMPARATOR
Intervention: Lactate-based control solution (C)
Number of subjects: 92
Study 9512112 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg + Amoxicillin 1.5 g (LA group; 21 patients)
Number of subjects: 57
Study 9512112 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg + Amoxicillin 1.5 g + Rebamipide 300 mg (LAM group; 36 patients)
Number of subjects: 57
Study 9512112 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM group
Number of subjects: 57
Study 9512112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study 7802317 — intervention group
Group type: EXPERIMENTAL
Intervention: Acelysin (water-soluble acetylsalicylic acid)
Number of subjects: 0
Study 7802317 — intervention group
Group type: EXPERIMENTAL
Intervention: Acelysin infusion
Number of subjects: 0
Study 3054452 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) followed 1 hour later by 5‐fluorouracil (5‐FU) (sequence MF)
Number of subjects: 127
Study 3054452 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil followed after 1 hour by methotrexate (sequence FM)
Number of subjects: 127
Study 29579482 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded maternal voice
Number of subjects: 136
Study 29579482 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk odor
Number of subjects: 136
Study 29579482 — intervention group
Group type: EXPERIMENTAL
Intervention: Incubator cover
Number of subjects: 136
Study 29579482 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 136
Study 27370231 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Number of subjects: 120
Study 27370231 — intervention group
Group type: COMPARATOR
Intervention: Sham meditation
Number of subjects: 120
Study 27370231 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual control
Number of subjects: 120
Study 24737198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS applied ipsilaterally to the temporoparietal junction (n = 30)
Number of subjects: 61
Study 24737198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS applied contralaterally to the temporoparietal junction (n = 31)
Number of subjects: 61
Study 24423909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional liquid supplement designed for diabetes mellitus
Number of subjects: 69
Study 24423909 — intervention group
Group type: COMPARATOR
Intervention: Control group (common diet)
Number of subjects: 69
Study 19925605 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on arrhythmia surgery
Number of subjects: 150
Study 19925605 — intervention group
Group type: COMPARATOR
Intervention: Cardiac surgery (without add-on surgery)
Number of subjects: 150
Study 19925605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac surgery (both groups)
Number of subjects: 150
Study 18715244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal dinoprostone (2 mg once every 6 hours)
Number of subjects: 592
Study 18715244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (25 micrograms once every 4 hours)
Number of subjects: 592
Study 18715244 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical balloon catheter
Number of subjects: 592
Study 18715244 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal dinoprostone and intravaginal misoprostol
Number of subjects: 592
Study 18715244 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal dinoprostone, intravaginal misoprostol, and transcervical balloon catheter
Number of subjects: 592
Study 16907931 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10 mg day‐1; n=13)
Number of subjects: 26
Study 16907931 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg day‐1; n=13)
Number of subjects: 26
Study 16907931 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (quinapril + atorvastatin)
Number of subjects: 26
Study 12359796 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation
Number of subjects: 741
Study 12359796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 741
Study 10585386 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Influence (SI) program with boosters
Number of subjects: 52
Study 10585386 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Influence (SI) program without boosters
Number of subjects: 52
Study 10585386 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Influence (Decision-Making) (SI(DM)) program with boosters
Number of subjects: 52
Study 10585386 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 7851081 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration for tasks dominated by inference
Number of subjects: 0
Study 7851081 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration for tasks dominated by retrieval
Number of subjects: 0
Study 7851081 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-independence model
Number of subjects: 0
Study 7851081 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-dependence model
Number of subjects: 0
Study 7851081 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiment 2
Number of subjects: 0